Fasenra® (benralizumab) – New formulation approval
October 4, 2019 - AstraZeneca announced the FDA approval of Fasenra (benralizumab) single-dose autoinjector, for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Download PDF
